Keith Wilson, PhD
Dr. Keith E Wilson is President and CSO of Nalo Therapeutics, a venture capital funded company in oncology targeting recently discovered cancer biology. He has over 20 years’ experience of life sciences research and development, specializing in oncology and immunology. He has extensive experience of developing and executing novel discovery, clinical and portfolio strategies, with experience bringing programs from discovery to market products. His last role was CSO at Oxford Biotherapeutics where he was responsible for their preclinical and clinical antibody drug conjugate portfolio and establishing their immune-oncology approach. Previously, he was Director, Biologics Technology and Global Leader, Antibody Drug Conjugates at AbbVie, where he was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team. He has also held positions as Senior Director of Research at Facet Biotech, prior to which he was Director, Pipeline Strategy / Early Discovery and Computational Biology at PDL BioPharma and began his career at Eos Biotechnology. Dr. Wilson holds a PhD in Biochemistry and Molecular Biology from the Oregon Health Sciences University did his post-doctoral research at Stanford University.